Related Experiment Videos
[Pharmacokinetics of ceftazidime injected peritoneally in continuous ambulatory peritoneal dialysis]
Abstract:
Peritonitis is the most frequent complication in patients under continuous ambulatory peritoneal dialysis. Intraperitoneal administration of ceftazidime in a dose of 125 mg per liter dialysate achieved serum concentrations higher than the minimal inhibitory concentrations of most organisms in spite of low peritoneal clearance. Serum concentration was stable up to the 120th hour. Dialysate osmolarity had no influence on serum concentration, peritoneal absorption or clearance of ceftazidime. Peritoneal inflammation did not cause changes in ceftazidime pharmacokinetics. Ceftazidime used alone as the first choice treatment was successful in 85%, of cases.
Insights
Ceftazidime effectively treats peritonitis in continuous ambulatory peritoneal dialysis patients. Intraperitoneal administration achieves therapeutic serum levels, proving successful in 85% of cases, even with inflammation.
Area of Science:
- Nephrology
- Infectious Diseases
- Pharmacology
Context:
- Peritonitis is a common complication in patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
- Effective antibiotic management is crucial for managing CAPD-related peritonitis.
Purpose:
- To evaluate the pharmacokinetics and efficacy of intraperitoneally administered ceftazidime in CAPD patients with peritonitis.
Summary:
- Intraperitoneal ceftazidime (125 mg/L dialysate) achieved adequate serum concentrations, exceeding minimal inhibitory concentrations for most pathogens.
- Serum ceftazidime levels remained stable for up to 120 hours.
- Dialysate osmolarity and peritoneal inflammation did not significantly alter ceftazidime pharmacokinetics.
- Ceftazidime monotherapy demonstrated an 85% success rate in treating peritonitis.
Impact:
- Provides evidence for ceftazidime as a safe and effective first-line treatment for peritonitis in CAPD patients.
- Supports optimized antibiotic dosing strategies in peritoneal dialysis settings.
- Highlights the reliability of intraperitoneal ceftazidime delivery for achieving systemic therapeutic levels.